Ixekizumab May Improve Early Response After Secukinumab Failure - Takeaways - MDSpire

Ixekizumab May Improve Early Response After Secukinumab Failure

A real-world cohort found faster early skin responses with ixekizumab than with guselkumab or ustekinumab following secukinumab treatment failure, while all three biologics demonstrated favorable safety.

  • By

  • Andrea Surnit

  • July 22, 2026

  • 4 min

Share

  • 1

    Ixekizumab showed faster early skin responses than guselkumab or ustekinumab after secukinumab treatment failure in a real-world cohort.

  • 2

    67% of patients switching to ixekizumab achieved PASI 75 at week 12, compared to 28% with guselkumab and 17% with ustekinumab.

  • 3

    The study evaluated 59 patients with moderate-to-severe plaque psoriasis who switched biologics due to treatment failure or adverse events.

  • 4

    Safety profiles were similar across all treatment groups, with 20% of patients experiencing mild adverse events.

  • 5

    Subgroup analyses indicated that treatment history may influence response to biologic switching, though findings were not statistically significant.

Original Source(s)

Ixekizumab May Improve Early Response After Secukinumab Failure

  • by Andrea Surnit

  • July 22, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Triglycerides Linked to Psoriasis Risk

Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models